Volume 20, Issue 4, 2022
Meet the Editorial Board Member
Pp: 661-661
Author(s): Gustav Akk
DOI: 10.2174/1570159X2004220328151242
Published on: 28 March, 2022
Uncoupling Protein 2 as a Pathogenic Determinant and Therapeutic Target in Cardiovascular and Metabolic Diseases
Pp: 662-674
Author(s): Rosita Stanzione*, Maurizio Forte, Maria Cotugno, Franca Bianchi, Simona Marchitti, Carla Letizia Busceti, Francesco Fornai and Speranza Rubattu*
DOI: 10.2174/1570159X19666210421094204
Published on: 24 February, 2022
Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development
Pp: 675-692
Author(s): Shiveena Bhatia, Rishi Rawal, Pratibha Sharma, Tanveer Singh, Manjinder Singh* and Varinder Singh*
DOI: 10.2174/1570159X19666210517114016
Published on: 24 February, 2022
Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)
Pp: 693-712
Author(s): Tommaso B. Jannini, Giorgio D. Lorenzo, Emanuela Bianciardi, Cinzia Niolu, Massimiliano Toscano, Giacomo Ciocca, Emmanuele A. Jannini and Alberto Siracusano*
DOI: 10.2174/1570159X19666210517150418
Published on: 24 February, 2022
Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Pp: 713-737
Author(s): Tao-Ran Li, Qin Yang, Xiaochen Hu and Ying Han*
DOI: 10.2174/1570159X19666210524153901
Published on: 24 February, 2022
Potential Mechanisms and Clinical Effectiveness of Acupuncture in Depression
Pp: 738-750
Author(s): Na-Na Yang , Lu-Lu Lin , Yue-Jie Li , Hong-Ping Li, Yan Cao, Chun-Xia Tan, Xiao-Wan Hao , Si-Ming Ma, Lu Wang and Cun-Zhi Liu*
DOI: 10.2174/1570159X19666210609162809
Published on: 24 February, 2022
Pathways Involved in Remyelination after Cerebral Ischemia
Pp: 751-765
Author(s): Gonzalo Garcia-Martin, Berta Alcover-Sanchez, Francisco Wandosell and Beatriz Cubelos*
DOI: 10.2174/1570159X19666210610093658
Published on: 24 February, 2022
Effects of Di-2-Ethylhexyl Phthalate on Central Nervous System Functions: A Narrative Review
Pp: 766-776
Author(s): Soheila Safarpour, Maryam Ghasemi-Kasman*, Samaneh Safarpour and Yasaman Mahdizadeh Darban
DOI: 10.2174/1570159X19666210713122517
Published on: 05 January, 2022
Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention
Pp: 777-781
Author(s): Konrad Rejdak and Paweł Grieb*
DOI: 10.2174/1570159X19666210729123734
Published on: 28 December, 2021
Microtubule-modulating Agents in the Fight Against Neurodegeneration: Will it ever Work?
Pp: 782-798
Author(s): Ahmed Soliman , Lidia Bakota and Roland Brandt *
DOI: 10.2174/1570159X19666211201101020
Published on: 24 February, 2022
Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Pp: 799-808
Author(s): Win Ning Chen, Mohd Farooq Shaikh*, Saatheeyavaane Bhuvanendran, Abhijit Date, Mohammad Tahir Ansari, Ammu Kutty Radhakrishnan and Iekhsan Othman
DOI: 10.2174/1570159X19666210528155801
Published on: 10 March, 2022
Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review
Pp: 809-819
Author(s): Jan Van Amsterdam*, Tibor M. Brunt, Filipa R. Pereira, Cleo L. Crunelle and Wim Van Den Brink
DOI: 10.2174/1570159X19666210610094352
Published on: 24 February, 2022